Effect of gemigliptin on cardiac ischemia/reperfusion and spontaneous hypertensive rat models
The Korean Journal of Physiology and Pharmacology
;
: 329-334, 2019.
Article
in English
| WPRIM
| ID: wpr-761803
ABSTRACT
Diabetes is associated with an increased risk of cardiovascular complications. Dipeptidyl peptidase-4 (DPP-IV) inhibitors are used clinically to reduce high blood glucose levels as an antidiabetic agent. However, the effect of the DPP-IV inhibitor gemigliptin on ischemia/reperfusion (I/R)-induced myocardial injury and hypertension is unknown. In this study, we assessed the effects and mechanisms of gemigliptin in rat models of myocardial I/R injury and spontaneous hypertension. Gemigliptin (20 and 100 mg/kg/d) or vehicle was administered intragastrically to Sprague-Dawley rats for 4 weeks before induction of I/R injury. Gemigliptin exerted a preventive effect on I/R injury by improving hemodynamic function and reducing infarct size compared to the vehicle control group. Moreover, administration of gemigliptin (0.03% and 0.15%) powder in food for 4 weeks reversed hypertrophy and improved diastolic function in spontaneously hypertensive rats. We report here a novel effect of the gemigliptin on I/R injury and hypertension.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Rats, Inbred SHR
/
Blood Glucose
/
Rats, Sprague-Dawley
/
Models, Animal
/
Hemodynamics
/
Hypertension
/
Hypertrophy
Limits:
Animals
Language:
English
Journal:
The Korean Journal of Physiology and Pharmacology
Year:
2019
Type:
Article
Similar
MEDLINE
...
LILACS
LIS